Cartesian Price Book Value Ratio from 2010 to 2025
| RNAC Stock | 14.70 0.34 2.37% |
Price Book Value Ratio | First Reported 2010-12-31 | Previous Quarter (408.41) | Current Value (387.99) | Quarterly Volatility 245.65432305 |
Check Cartesian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cartesian Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 21.7 M or Total Revenue of 30.2 M, as well as many indicators such as Price To Sales Ratio of 67.82, Dividend Yield of 0.0 or Days Sales Outstanding of 7.77. Cartesian financial statements analysis is a perfect complement when working with Cartesian Therapeutics Valuation or Volatility modules.
Cartesian | Price Book Value Ratio |
Latest Cartesian Therapeutics' Price Book Value Ratio Growth Pattern
Below is the plot of the Price Book Value Ratio of Cartesian Therapeutics over the last few years. It is Cartesian Therapeutics' Price Book Value Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cartesian Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Price Book Value Ratio | 10 Years Trend |
|
Price Book Value Ratio |
| Timeline |
Cartesian Price Book Value Ratio Regression Statistics
| Arithmetic Mean | (36.63) | |
| Geometric Mean | 108.64 | |
| Coefficient Of Variation | (670.56) | |
| Mean Deviation | 177.98 | |
| Median | (51.32) | |
| Standard Deviation | 245.65 | |
| Sample Variance | 60,346 | |
| Range | 839 | |
| R-Value | (0.23) | |
| Mean Square Error | 61,352 | |
| R-Squared | 0.05 | |
| Significance | 0.40 | |
| Slope | (11.66) | |
| Total Sum of Squares | 905,191 |
Cartesian Price Book Value Ratio History
About Cartesian Therapeutics Financial Statements
Cartesian Therapeutics stakeholders use historical fundamental indicators, such as Cartesian Therapeutics' Price Book Value Ratio, to determine how well the company is positioned to perform in the future. Although Cartesian Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cartesian Therapeutics' assets and liabilities are reflected in the revenues and expenses on Cartesian Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cartesian Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price Book Value Ratio | (408.41) | (387.99) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Cartesian Therapeutics Correlation against competitors. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cartesian Therapeutics. If investors know Cartesian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cartesian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.537 | Earnings Share (4.49) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cartesian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cartesian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cartesian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.